CLINICAL TRIAL SUMMARY

MDACC Study No:CERN09-02 (clinicaltrials.gov NCT No: NCT01295944)
Title:Phase II trial of carboplatin and bevacizumab for the treatment of recurrent low-grade and anaplastic supratentorial, infratentorial and spinal cord ependymoma in adults
Principal Investigator:Mark R. Gilbert
Treatment Agent:Bevacizumab; Carboplatin
Study Status:Open
Study Description:The goal of this clinical research study is to learn if the combination of
bevacizumab and carboplatin can help to control recurrent ependymoma. The
safety of this drug combination will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Brain; Spinal
Phase of Study:Phase II
Treatment Agents:Bevacizumab
Carboplatin
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:CERN
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Mark R. Gilbert
Dept:Neuro Oncology
For Clinical Trial Enrollment:713-792-2883
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults